Huapont Life Sciences Co Ltd (002004) - Total Liabilities
Based on the latest financial reports, Huapont Life Sciences Co Ltd (002004) has total liabilities worth CN¥12.49 Billion CNY (≈ $1.83 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Huapont Life Sciences Co Ltd (002004) equity growth momentum to track the company's year-over-year net asset growth rate.
Huapont Life Sciences Co Ltd - Total Liabilities Trend (2001–2025)
This chart illustrates how Huapont Life Sciences Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 002004 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Huapont Life Sciences Co Ltd Competitors by Total Liabilities
The table below lists competitors of Huapont Life Sciences Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gravita India Limited
NSE:GRAVITA
|
India | Rs9.59 Billion |
|
The India Cements Limited
NSE:INDIACEM
|
India | Rs32.79 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥2.68 Billion |
|
Tekfen Holding AS
IS:TKFEN
|
Turkey | TL39.41 Billion |
|
Suzhou Victory Precision Manufacture Co Ltd
SHE:002426
|
China | CN¥4.18 Billion |
|
Guangdong Tapai Group Co Ltd
SHE:002233
|
China | CN¥1.17 Billion |
|
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.
SHG:605016
|
China | CN¥717.55 Million |
|
Suzhou Anjie Technology Co Ltd
SHE:002635
|
China | CN¥2.40 Billion |
Liability Composition Analysis (2001–2025)
This chart breaks down Huapont Life Sciences Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 002004 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Huapont Life Sciences Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Huapont Life Sciences Co Ltd (2001–2025)
The table below shows the annual total liabilities of Huapont Life Sciences Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥12.05 Billion ≈ $1.76 Billion |
-13.79% |
| 2024-12-31 | CN¥13.98 Billion ≈ $2.05 Billion |
-1.17% |
| 2023-12-31 | CN¥14.14 Billion ≈ $2.07 Billion |
+4.97% |
| 2022-12-31 | CN¥13.47 Billion ≈ $1.97 Billion |
-5.25% |
| 2021-12-31 | CN¥14.22 Billion ≈ $2.08 Billion |
+0.93% |
| 2020-12-31 | CN¥14.09 Billion ≈ $2.06 Billion |
+5.20% |
| 2019-12-31 | CN¥13.39 Billion ≈ $1.96 Billion |
-2.97% |
| 2018-12-31 | CN¥13.80 Billion ≈ $2.02 Billion |
-12.61% |
| 2017-12-31 | CN¥15.79 Billion ≈ $2.31 Billion |
+16.78% |
| 2016-12-31 | CN¥13.52 Billion ≈ $1.98 Billion |
+45.42% |
| 2015-12-31 | CN¥9.30 Billion ≈ $1.36 Billion |
+18.68% |
| 2014-12-31 | CN¥7.84 Billion ≈ $1.15 Billion |
+115.56% |
| 2013-12-31 | CN¥3.64 Billion ≈ $531.96 Million |
+22.59% |
| 2012-12-31 | CN¥2.97 Billion ≈ $433.93 Million |
+84.93% |
| 2011-12-31 | CN¥1.60 Billion ≈ $234.64 Million |
+397.08% |
| 2010-12-31 | CN¥322.58 Million ≈ $47.20 Million |
+31.30% |
| 2009-12-31 | CN¥245.68 Million ≈ $35.95 Million |
-24.47% |
| 2008-12-31 | CN¥325.26 Million ≈ $47.60 Million |
-9.09% |
| 2007-12-31 | CN¥357.78 Million ≈ $52.35 Million |
+47.73% |
| 2006-12-31 | CN¥242.18 Million ≈ $35.44 Million |
+551.50% |
| 2005-12-31 | CN¥37.17 Million ≈ $5.44 Million |
-53.18% |
| 2004-12-31 | CN¥79.39 Million ≈ $11.62 Million |
-0.75% |
| 2003-12-31 | CN¥79.99 Million ≈ $11.71 Million |
-23.75% |
| 2002-12-31 | CN¥104.91 Million ≈ $15.35 Million |
+128.44% |
| 2001-12-31 | CN¥45.93 Million ≈ $6.72 Million |
-- |
About Huapont Life Sciences Co Ltd
Huapont Life Sciences Co.,Ltd. engages in the medicine, medical care, agrochemicals, new materials, tourism, and other businesses in China and internationally. The company is involved in the production and sale of pharmaceutical preparations and raw materials. It also offers medicines for skin, tuberculosis, anti-infection, respiratory, anti-tumor, and cardiovascular, as well as health management… Read more